Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma
Launched by INSTITUT CURIE · May 24, 2019
Trial Information
Current as of June 25, 2025
Unknown status
Keywords
ClinConnect Summary
The aim of the research is to study the activity of PD-1 inhibitors in patients with metastatic uveal melanoma and treated by Nivolumab and Pembrolizumab. These molecules have already received the authorities approvals. The data collected will be crucial for the understanding of the mechanism of PD-1 inhibitors and also for the futures studies.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with metastatic uveal melanoma
- • Patients who received at least once injection of Nivolumab or Pembrolizumab in the case of the disease's treatment
- Exclusion Criteria:
- • Antecedent of another evolutionary tumor pathology
About Institut Curie
Institut Curie is a prestigious French research institute dedicated to the fight against cancer, renowned for its integration of cutting-edge research, innovative therapies, and comprehensive patient care. Established in 1909, it combines academic excellence with clinical expertise, facilitating groundbreaking studies and clinical trials aimed at advancing cancer treatment and improving patient outcomes. With a multidisciplinary approach, Institut Curie collaborates with leading scientists and healthcare professionals, fostering a dynamic environment for the development of novel therapeutic strategies and personalized medicine in oncology. Its commitment to research and patient-centered care positions Institut Curie as a pivotal player in the global cancer research community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, Ile De France, France
Patients applied
Trial Officials
Manuel Rodrigues, MD
Study Director
Institut Curie
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials